Treatment of severe Crohn's disease using antimycobacterial triple therapy--approaching a cure? (Q28211872)

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Preliminary report on isolation of mycobacteria from patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Mycobacterium paratuberculosis DNA in Crohn's disease tissue

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Polymerase chain reaction detection of Mycobacterium paratuberculosis and Mycobacterium avium subsp silvaticum in long term cultures from Crohn's disease and control tissues

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Identification of spheroplast-like agents isolated from tissues of patients with Crohn's disease and control tissues by polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Detection of Mycobacterium paratuberculosis by Polymerase Chain Reaction in Children with Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Mycobacterium paratuberculosis in intestinal tissue from patients with Crohn's disease demonstrated by a nested primer polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Mycobacterium paratuberculosis: a potential food-borne pathogen?

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Etiological role of mycobacterium in Crohn's disease: An assessment of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Letter: Dapsone in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Antimycobacterial chemotherapy in two cases of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Antimycobacterial therapy ineffective in Crohn's disease after a year

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Controlled trial of rifampicin and ethambutol in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Activities of clarithromycin, azithromycin, and ofloxacin in combination with liposomal or unencapsulated granulocyte-macrophage colony-stimulating factor against intramacrophage Mycobacterium avium-Mycobacterium intracellulare

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Antimicrobial activity of rifabutin in combination with two and three other antimicrobial agents against strains of Mycobacterium paratuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Activity of clarithromycin compared with those of other drugs against Mycobacterium paratuberculosis and further enhancement of its extracellular and intracellular activities by ethambutol

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Antimycobacterial synergism of clarithromycin and rifabutin

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Intracellular accumulation of azithromycin by cultured human fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

In-vitro concentration of azithromycin in human phagocytic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

A simple index of Crohn's-disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Cure of duodenal ulcer after eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Acquired resistance in Mycobacterium avium complex strains isolated from AIDS patients and beige mice during treatment with clarithromycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Genetic diversity and evidence for acquired antimicrobial resistance in Mycobacterium tuberculosis at a large hospital in South India

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Activity of rifabutin alone and in combination with clofazimine, kanamycin and ethambutol against Mycobacterium intracellulare infections in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS1590-8658%2802%2980056-1

7 January 2021

10.1016/S1590-8658(02)80056-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

792005

792005

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference